ELVN
NASDAQEnliven Therapeutics Inc.
Price$37.35-0.59 (-1.56%)
01:30 PM07:45 PM
News · 26 weeks60+267%
2026-04-192026-10-11
Mix2590d
- Insider10(40%)
- Other5(20%)
- SEC Filings5(20%)
- Analyst4(16%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Enliven Therapeutics Inc.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 3 filed by Enliven Therapeutics Inc.3 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form 8-K filed by Enliven Therapeutics Inc.8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearAccomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readinessEnliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-endBURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Kristine Ball to its Board of Directors, effective immediately. Ms. Ball brings more than 20 years of executive experience across clinical-stage and
- PREnliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaEnliven remains on track to initiate ENABLE-2 before year-end 2026BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML).United States Adopted Names (USAN) Council has adopted relcobatinib as the nonproprietary name for ELVN-001. Relcobatinib is an investigational, p
- INSIDERSEC Form 4 filed by Enliven Therapeutics Inc.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Enliven Therapeutics with a new price targetMorgan Stanley initiated coverage of Enliven Therapeutics with a rating of Overweight and set a new price target of $70.00
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- ANALYSTAnalyst initiated coverage on Enliven Therapeutics with a new price targetAnalyst initiated coverage of Enliven Therapeutics with a rating of Overweight and set a new price target of $75.00
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,982 shares at a strike of $14.85 and sold $303,003 worth of shares (6,018 units at $50.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 38,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $251,754 worth of shares (5,000 units at $50.35) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- PREnliven Therapeutics to Present at Upcoming Investor ConferencesBURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, Sept. 8, 2026Location: Boston, MAForum: 1x1 MeetingsBaird 2026 Global Healthcare ConferenceDate: Tuesday, Sept. 15, 2026Location: New York, NYForum: Fireside Chat and 1x1 MeetingsMorgan Stanley 24th Annual Global Healthcare ConferenceDate: Wednesday, Sept. 16, 2026Location: New York, NYForum: Fireside Chat and 1x1 Meet
- PREnliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingBURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas. This is an encore presentation of data that were previously presented at the European Hematology Association (EHA) 2026 Congress.Details of the presentation are as follows
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin sold $352,551 worth of shares (6,018 units at $58.58) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 40,036 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $292,931 worth of shares (5,000 units at $58.59) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- ANALYSTWilliam Blair initiated coverage on Enliven TherapeuticsWilliam Blair initiated coverage of Enliven Therapeutics with a rating of Outperform
- ANALYSTBarclays initiated coverage on Enliven Therapeutics with a new price targetBarclays initiated coverage of Enliven Therapeutics with a rating of Overweight and set a new price target of $78.00
- INSIDERDirector Derynck Mika K exercised 158,795 shares at a strike of $10.84 and sold $9,561,587 worth of shares (158,795 units at $60.21) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Enliven Therapeutics Inc.SCHEDULE 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 10-Q filed by Enliven Therapeutics Inc.10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAnnounced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profileReached alignment with the FDA on key Phase 3 trial design componentsStrong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030BURLINGAME, Calif., Aug. 5, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a busines
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin sold $316,780 worth of shares (6,018 units at $52.64) as part of a pre-agreed trading plan and exercised 1,072 shares at a strike of $2.48, decreasing direct ownership by 10% to 46,054 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $263,373 worth of shares (5,000 units at $52.67) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
ELVN FAQ
6 questionsWhere does ELVN stock trade?
Enliven Therapeutics Inc. (ELVN) is listed on NASDAQ.What sector and industry is ELVN in?
Enliven Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enliven Therapeutics Inc. go public?
Enliven Therapeutics Inc. (ELVN) completed its IPO in 2020.What are analysts saying about ELVN?
Enliven Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight on 2026-10-02. Recent price targets range from $3700.00 to $4200.00.What companies are similar to ELVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ELVN side-by-side with any of them on Quantisnow.How can I track ELVN on Quantisnow?
Quantisnow aggregates Enliven Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELVN to receive live email and push alerts on every new disclosure.